ArticleIJTLD open2026
Implementation insights into bridging the gaps in isoniazid preventive therapy uptake in adults with HIV.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTB remains the leading opportunistic infection among people living with HIV (PLHIV). Isoniazid preventive therapy (IPT) is a key strategy for TB prevention, yet uptake remains suboptimal. This study examined barriers and facilitators to IPT uptake among adult PLHIV and health care providers (HCPs) using the Consolidated Framework for Implementation Research (CFIR).
methodsA cross-sectional, mixed-methods study was conducted at the BJ Government Medical College ART Centre, Pune, India, from May 2022 to July 2023. Qualitative data from 11 in-depth interviews (5 PLHIV, 6 HCPs) were thematically analysed using MAXQDA-2022, and quantitative data from 201 PLHIV were analysed using R.
resultsAmong 201 PLHIV, 50% (n = 100) completed IPT, 38% (n = 77) missed doses, and 23% (n = 47) reported side effects. Integrated analysis identified drug stock-outs as the dominant system-level barrier, alongside facility-level constraints such as limited counselling due to staff shortages. Individual-level barriers included fear of side effects and time constraints. Facilitators included effective counselling, family support, perceived preventive benefits, motivation, and trust in providers. HCPs emphasised assertive counselling, routine IPT prescription, and regular follow-up as critical to improving IPT completion.
conclusionEnsuring an uninterrupted drug supply, sufficient staffing, and structured counselling is essential for strengthening IPT implementation within HIV programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.